Millie Nelson

In a bid to bolster its efforts in the gene therapy and neuroscience space, Novartis has acquired Kate Therapeutics for up to $1.1 billion.

The LSX European Lifestars Awards (ELAs) in London, UK gathered life science executives and partners to celebrate their achievements over the past 12 months.

Better data equals better solutions said panelists at LSX Nordics Congress, but collaborations must create behavioral changes to drive innovation.

Bayer will provide facility access and tailored mentorship at its recently opened life science incubator, Co.Lab.

MFX, Tolemy Bio, and AminoAcids join forces to advance model-driven media optimization for cell and gene therapies.

We sat down with Judy Chou, CEO of AllTruBio, to delve into the details of the company’s recent $225 million Series B financing round.

The acquisition will see AbbVie gain Nimble Therapeutics’ lead candidate, an oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis.

GSK is investing $1 billion upfront to expand its oncology portfolio by acquiring rare cancer therapy developer IDRx.

Johnson & Johnson got the J.P. Morgan Healthcare Conference off to a flying start with its $14.6 billion Intra-Cellular Therapies buy.

Gilead will expand its inflammation portfolio by securing exclusive global rights to LEO Pharma’s preclinical oral STAT6 program.